Physician profile
Daphne Lashbrook
NPI 1538162979
$2,541.20
in general payments reported to CMS, 2019-2025
24 companies · $475 in 2025
The $475 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $67.62 · 2021: $202 · 2022: $284 · 2023: $628 · 2024: $499 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.24 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $402.49 | 2022-2025 | |
| Organon LLC | $308.79 | 2022-2025 | Nexplanon |
| Astellas Pharma US INC | $252.51 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $126.71 | 2019-2025 | |
| Hologic Sales and Service, LLC | $115.23 | 2023-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Pfizer INC. | $93.83 | 2019-2025 | |
| Conmed Corporation | $83.33 | 2023 | Airseal |
| Merck Sharp & Dohme LLC | $77.16 | 2019 | |
| Millicent US INC | $59.34 | 2023-2024 | Intrarosa, Femring |
| Allergan, INC. | $56.69 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $52.96 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $51.66 | 2024-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $50.82 | 2019 | |
| Vertical Pharmaceuticals, LLC | $44.94 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $36.43 | 2025 | Dexcom G6 Transmitter |
| Minerva Surgical, INC | $32.97 | 2024 | |
| Biogen, INC. | $26.36 | 2024 | Zurzuvae |
| Medtronic, INC. | $19.39 | 2024 | Symplicity G3 |
| Exeltis, USA INC. | $18.54 | 2024 | Slynd |
| Agile Therapeutics, INC. | $18.05 | 2024 | Twirla |
| Sage Therapeutics, LLC | $17.69 | 2024 | |
| Coopersurgical, INC. | $16.86 | 2025 | Paragard T 380a |
| Meditrina | $12.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Lashbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.